The newly appointed head of the FDA is following through on his commitment to combat the growing opioid abuse epidemic.
Food and Drug Administration Commissioner Scott Gottlieb May 23 announced he is establishing an opioid steering committee to explore and develop tools the agency can use to combat the epidemic. In April, at his confirmation hearing, Gottlieb told the Senate Health, Education, Labor, and Pensions Committee that the opioid epidemic would be his highest priority.
The steering committee’s first actions will be to address three questions, including whether the FDA should require some form of mandatory education for health-care professionals who prescribe opioids; whether the agency should take additional steps under its risk management authorities on opioid prescribing; and whether the FDA is using the proper policy framework to consider the risk of abuse and misuse as part of the drug review process for opioids.
“Despite the efforts of FDA and many other public health agencies, the scope of the epidemic continues to grow, and the human and economic costs are staggering,” Gottlieb said. “Working together, we need to do all we can to get ahead of this crisis. That’s why we’ll also be soliciting public input, through various forums, on what additional steps FDA should consider.”
The biopharmaceutical industry wants to help Gottlieb with his efforts.
Jim Greenwood, president and chief executive officer of the Biotechnology Innovation Organization (BIO), said in a statement “America’s biopharmaceutical companies are committed to finding solutions to help curb opioid abuse.”
“Several of our member companies are developing non-addictive, next generation therapies with the potential to transform the standard of care for pain management,” Greenwood said. “They are also working to develop new opioid formulations that prevent or deter improper use, such as tamper-proof pills, and taking steps to increase their prescriber education efforts.”
Greenwood said BIO will work with Gottlieb and the committee “to better meet the needs of patients with chronic and acute pain.”
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)